United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - isotretinoin - oral capsule - 20mg

United States - English - NLM (National Library of Medicine)

ranbaxy laboratories inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - capsule, gelatin coated - 10 mg - sotret is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, sotret should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, sotret is indicated only for those female patients who are not pregnant, because sotret can cause severe birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin caps

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - isotretinoin - oral capsule - 20mg

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - isotretinoin, quantity: 30 mg - capsule, soft - excipient ingredients: soya oil; disodium edetate; partially hydrogenated soya oil; hydrogenated soya oil; yellow beeswax; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; titanium dioxide; iron oxide red; butylated hydroxyanisole; dl-alpha-tocopherol - treatment of severe cystic acne. a single course of therapy has been shown to result in complete and prolonged remission of disease in many patients. if a second course of therapy is needed, it should not be initiated until at least eight weeks after completion of the first course, since experience has shown that patients may continue to improve while off the drug. because of significant adverse effects associated with its use, isotretinoin should be reserved for patients with severe cystic acne who are unresponsive to conventional therapy, including systemic antibiotics.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - isotretinoin - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

crawford healthcare ltd - isotretinoin - oral capsule - 20mg